Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Equillium Inc (EQ)
Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,950
  • Shares Outstanding, K 34,414
  • Annual Sales, $ 15,759 K
  • Annual Income, $ -39,050 K
  • 60-Month Beta 1.23
  • Price/Sales 1.42
  • Price/Cash Flow N/A
  • Price/Book 0.79
Trade EQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.26
  • Most Recent Earnings -0.40 on 11/14/22
  • Next Earnings Date 05/11/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 533.26% ( +533.26%)
  • Historical Volatility 113.67%
  • IV Percentile 96%
  • IV Rank 49.16%
  • IV High 1,083.99% on 01/13/23
  • IV Low 0.76% on 06/08/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 358
  • Open Int (30-Day) 411

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.27
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.29
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5200 +39.42%
on 03/13/23
0.9600 -24.48%
on 03/06/23
-0.1850 (-20.33%)
since 02/24/23
3-Month
0.5200 +39.42%
on 03/13/23
1.3500 -46.30%
on 02/02/23
-0.1650 (-18.54%)
since 12/23/22
52-Week
0.5200 +39.42%
on 03/13/23
3.4355 -78.90%
on 03/28/22
-2.5650 (-77.96%)
since 03/24/22

Most Recent Stories

More News
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.7250 (+11.54%)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7250 (+11.54%)
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation...

EQ : 0.7250 (+11.54%)
Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.7250 (+11.54%)
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was...

EQ : 0.7250 (+11.54%)
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

EQ : 0.7250 (+11.54%)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited,...

EQ : 0.7250 (+11.54%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MVBF : 21.25 (+1.19%)
EQ : 0.7250 (+11.54%)
MTCR : 0.5723 (+0.40%)
SESN : 0.6288 (+7.29%)
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

EQ : 0.7250 (+11.54%)
IMGO : 36.01 (+0.03%)
MTCR : 0.5723 (+0.40%)
OPNT : 20.65 (-0.58%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBCF, PFHD, EQ, MTCR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SBCF : 24.19 (+1.60%)
PFHD : 28.65 (-0.52%)
EQ : 0.7250 (+11.54%)
MTCR : 0.5723 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 0.8333
2nd Resistance Point 0.7817
1st Resistance Point 0.7533
Last Price 0.7250
1st Support Level 0.6733
2nd Support Level 0.6217
3rd Support Level 0.5933

See More

52-Week High 3.4355
Fibonacci 61.8% 2.3218
Fibonacci 50% 1.9777
Fibonacci 38.2% 1.6337
Last Price 0.7250
52-Week Low 0.5200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar